About Verona Pharma
Verona Pharma is a company based in London (United Kingdom) founded in 2005 was acquired by Merck in July 2025.. Verona Pharma has raised $56.02 million across 4 funding rounds from investors including Merck, Orbimed and Janus Henderson Investors. The company has 209 employees as of December 31, 2024. Verona Pharma offers products and services including Respiratory Therapeutics and Pipeline Programs. Verona Pharma operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.
- Headquarter London, United Kingdom
- Employees 209 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Verona Pharma Plc Sponsored Adr
-
Annual Revenue
$42.3 M0as on Dec 31, 2024
-
Net Profit
$-173.49 M-217.87as on Dec 31, 2024
-
EBITDA
$-153.63 M-128.79as on Dec 31, 2024
-
Total Equity Funding
$56.02 M (USD)
in 4 rounds
-
Latest Funding Round
$200.16 M (USD), Post-IPO
Jul 17, 2020
-
Investors
Merck
& 16 more
-
Employee Count
209
as on Dec 31, 2024
-
Acquired by
Merck
(Jul 09, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Verona Pharma
Verona Pharma is a publicly listed company on the NASDAQ with ticker symbol VRNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Verona Pharma
Verona Pharma offers a comprehensive portfolio of products and services, including Respiratory Therapeutics and Pipeline Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments for chronic respiratory diseases like COPD.
Builds portfolio of novel respiratory drugs for various conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Verona Pharma
Verona Pharma has successfully raised a total of $56.02M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200.16 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $200.2M
-
First Round
First Round
(06 Feb 2012)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2020 | Amount | Post-IPO - Verona Pharma | Valuation |
investors |
|
| Jun, 2016 | Amount | Series C - Verona Pharma | Valuation |
investors |
|
| Nov, 2014 | Amount | Grant - Verona Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Verona Pharma
Verona Pharma has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Orbimed and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Verona Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Verona Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Verona Pharma Comparisons
Competitors of Verona Pharma
Verona Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Protein biologics are developed for treating rare diseases.
|
|
| domain | founded_year | HQ Location |
Precision medicines for lung-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
|
|
| domain | founded_year | HQ Location |
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Verona Pharma
Frequently Asked Questions about Verona Pharma
When was Verona Pharma founded?
Verona Pharma was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Where is Verona Pharma located?
Verona Pharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Is Verona Pharma a funded company?
Verona Pharma is a funded company, having raised a total of $56.02M across 4 funding rounds to date.
How many employees does Verona Pharma have?
As of Dec 31, 2024, the latest employee count at Verona Pharma is 209.
What is the annual revenue of Verona Pharma?
Annual revenue of Verona Pharma is $42.3M as on Dec 31, 2024.
What does Verona Pharma do?
Verona Pharma was founded in 2005 in London, United Kingdom, and operates in the pharmaceutical sector focused on respiratory conditions. A drug pipeline is maintained, including RPL-554 in Phase 2 trials for chronic obstructive pulmonary disease, cystic fibrosis, and asthma. VRP700 for cough management is available for out-licensing. Novel anti-inflammatory polysaccharides from marine organisms like starfish are also identified as sources without anticoagulant effects.
Who are the top competitors of Verona Pharma?
Verona Pharma's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
What products or services does Verona Pharma offer?
Verona Pharma offers Respiratory Therapeutics and Pipeline Programs.
Is Verona Pharma publicly traded?
Yes, Verona Pharma is publicly traded on NASDAQ under the ticker symbol VRNA.
Who are Verona Pharma's investors?
Verona Pharma has 17 investors. Key investors include Merck, Orbimed, Janus Henderson Investors, RA Capital, and Perceptive Advisors.
What is Verona Pharma's ticker symbol?
The ticker symbol of Verona Pharma is VRNA on NASDAQ.